Tildacerfont
Based on 1 Customer Validation
Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia.
For research use only. We do not sell to patients.
- Purity: 98.60%
- CAS No.: 1014983-00-6
- Formula: C20H26ClN5OS
- Molecular Weight:419.97
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Biological Activity
|
CRFR1 |
Tildacerfont is a CRF1 receptor antagonist that acts on the hypothalamic-pituitary-adrenal (HPA) axis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1014983-00-6
-
Appearance Solid
-
Molecular Weight 419.97
-
Formula C20H26ClN5OS
-
Color Light yellow to yellow
-
SMILES
CCC(CC)C1=CC(C)=NC2=C(C(C)=NN12)C3=C(N=C(S3)N4CCOCC4)Cl
-
Synonyms
SPR001; LY2371712
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
DMSO : 10 mg/mL (23.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3811 mL | 11.9056 mL | 23.8112 mL | 59.5281 mL |
| 5 mM | 0.4762 mL | 2.3811 mL | 4.7622 mL | 11.9056 mL | |
| 10 mM | 0.2381 mL | 1.1906 mL | 2.3811 mL | 5.9528 mL | |
| 15 mM | 0.1587 mL | 0.7937 mL | 1.5874 mL | 3.9685 mL | |
| 20 mM | 0.1191 mL | 0.5953 mL | 1.1906 mL | 2.9764 mL |
- Tildacerfont
- 1014983-00-6
- SPR001
- LY2371712
- SPR 001
- SPR-001
- LY2371712
- LY 2371712
- LY-2371712
- CRFR
- corticotropin-releasing factor type 1 (CRF1) receptor
- androstenedione
- CYP3A4
- 21-hydroxylase deficiency congenital adrenal hyperplasia (21OHD-CAH)
- glucocorticoid
- pituitary ACTH
- testicular adrenal rest tissue
- 17-hydroxyprogesterone
- dexamethasone
- Inhibitor
- inhibitor
- inhibit